Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Antonio Ungaro
Observed names:
A. Ungaro,
Ungaro, Antonio
Institution:
Azienda Ospedaliera S.Giuseppe Moscati
Observed institutions:
Azienda Ospedaliera S.Giuseppe Moscati,
Azienda Ospedaliera Fatebenefratelli e Oftalmico,
Ospedale San Luigi Gonzaga,
University of Turin,
University of Bari Aldo Moro,
European Institute of Oncology
show all 6
ORCID:
0000-0003-0548-2611
Observed ORCID:
0000-0003-0548-2611
OpenAlex ID:
A5082664540
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside
2022
·
Antonio Ungaro
, Marcello Tucci
, et al.
·
Cells
·
47
PDF
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond
2022
·
Alessandro Audisio
, Consuelo Buttigliero
, et al.
·
Cells
·
41
PDF
Ischemic Cardiopathy from CIS-Diamminedichloroplatinum (CDDP)
1984
·
Maurizio Tomirotti
, Romeo Riundi
, et al.
·
Tumori Journal
·
39
The role of multimodal treatment in patients with advanced lung neuroendocrine tumors
2017
·
Nicola Fazio
, Antonio Ungaro
, et al.
·
Journal of Thoracic Disease
·
22
PDF
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors
2018
·
Marta Peri
, Edoardo Botteri
, et al.
·
Journal of Thoracic Disease
·
20
PDF
Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors
2022
·
Marco Donatello Delcuratolo
, Marcello Tucci
, et al.
·
Critical Reviews in Oncology/Hematology
·
13
Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report
2016
·
Antonio Ungaro
, Franco Orsi
, et al.
·
ecancermedicalscience
·
11
PDF
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”
2025
·
Marco Donatello Delcuratolo
, Veronica Crespi
, et al.
·
Cancer Treatment Reviews
·
10
PDF
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer
2025
·
Francesco Passiglia
, Francesco Pepe
, et al.
·
Cancer
·
9
PDF
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
2022
·
Fabio Turco
, Marcello Tucci
, et al.
·
癌症:英文版
·
8
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?
2022
·
Marco Audisio
, Marcello Tucci
, et al.
·
Critical Reviews in Oncology/Hematology
·
8
Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives
2017
·
Ioana Lambrescu
, Simona Fica
, et al.
·
Cancer Treatment Reviews
·
8
Il ruolo della 18F-FDG PET/CT nella stadiazione dei pazienti con carcinoma esofageo
2019
·
Corinna Altini
, Artor Niccoli Asabella
, et al.
·
Recenti Progressi in Medicina
·
6
Patient Advocacy in Transforming Surgical Lung Cancer Care in Europe
2026
·
Cecilia Pompili
, Antonio Ungaro
, et al.
·
Interdisciplinary CardioVascular and Thoracic Surgery
·
2
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis
2022
·
Fabio Turco
, Marcello Tucci
, et al.
·
Tumori Journal
·
2
Emerging insights of drug resistance in metastatic castration resistant prostate cancer.
2022
·
A. Ungaro
, E. Parlagreco
, et al.
·
Annals of Research in Oncology
·
1
PDF
Systemic therapies in metastatic pancreatic neuroendocrine neoplasms (PNENs): is there a right sequence? A case report and review of the literature.
2016
·
Spada, Francesca
, Gelsomino, Fabio
, et al.
·
European journal of oncology
·
1
PDF
P3.016: Air Pollution Exposure Predicts ICI Outcomes in Advanced NSCLC: A Geospatially-Referenced Machine-Learning Multicenter Analysis
2026
·
A. Nuccio
, D. Zotti
, et al.
·
Journal of Thoracic Oncology
From supportive galenic compounding to advanced clinical pharmacy: A decade of excellence and safety in the Antiblastic Drugs Unit in Southern Italy (2014–2025)
2026
·
Filomena D'Amico
, Rosa Moscogiuri
, et al.
·
Journal of Oncology Pharmacy Practice
PDF
154eP Real-world effectiveness and resource utilization of first-line pembrolizumab in NSCLC: A retrospective observational study (MOSAICO study)
2026
·
A. Ungaro
, M. Calcagno
, et al.
·
ESMO Open
PDF
P3.18.18 Predictive Role of Respiratory Function Tests on Lung Toxicity in Stage III NSCLC Under Chemo-Radiotherapy and Durvalumab: Preludio Trial
2025
·
P.M. Medusa
, C.M. Della Corte
, et al.
·
Journal of Thoracic Oncology
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL
2025
·
P.M. Medusa
, N. Carro
, et al.
·
Lung Cancer
Show more works
View as search
Works count:
49
Citation count:
248
H-index:
9
I10-index:
8
Year
Topic
Type